GOG-0186H: A Randomized Phase II Evaluation of Weekly Paclitaxel (NSC #673089) Versus Weekly Paclitaxel with Oncolytic Reovirus (REOLYSIN® NSC # 729968, BB-IND # 13370) in the Treatment of Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer(NCT# 01199263)

The GOG-0186H termination was listed in error in today's (4/9/2018) weekly broadcast. Please revert back to the previous protocol document (amendment 11; version date: July 7, 2016) which is available on NRG Oncology. The termination document has been removed.

We apologize for the inconvenience.

View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.

Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103

Update Profile/Email Address